drugset / Trial / NCT01527370

Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)

NCT01527370

Phase 3 Completed 250 enrolled Merck Sharp & Dohme LLC
NaSingle-groupOpen-labelPrevention

Summary

This study will determine if ZOSTAVAX™ is safe, tolerable, and immunogenic in healthy adults in India.

Timeline

Start
2012-10-31
Primary completion
2013-04-09
Completion
2013-04-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Varivax Vaccine 0.65 ml Subcutaneous

Indications